Literature DB >> 9345057

AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily.

J Hillion1, M Le Coniat, P Jonveaux, R Berger, O A Bernard.   

Abstract

Fusion genes implicating the MLL gene have been recently demonstrated in various 11q23 chromosomal abnormalities in human hematopoietic malignancies. We analyzed a t(6;11)(q21;q23) translocation detected in a secondary acute myeloblastic leukemia. This translocation results in fusion of the MLL gene on 11q23 to a previously unknown gene on chromosome 6 that differs from the previously reported MLL partner gene AF6q. The novel gene, named AF6q21, encodes a forkhead (FH) protein with strong similarities to the two FH family members whose genes are already known to be involved in chromosomal translocations of human malignancies, AFX and FKHR. Strikingly, in these translocations the breakpoints are located at the same position within the FH domains. Therefore, AF6q21, AFX, and FKHR could define a new FH subfamily particularly involved in human malignancies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9345057

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B.

Authors:  H Takaishi; H Konishi; H Matsuzaki; Y Ono; Y Shirai; N Saito; T Kitamura; W Ogawa; M Kasuga; U Kikkawa; Y Nishizuka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Functional analysis of the leukemia protein ELL: evidence for a role in the regulation of cell growth and survival.

Authors:  R W Johnstone; M Gerber; T Landewe; A Tollefson; W S Wold; A Shilatifard
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).

Authors:  M Osaka; J D Rowley; N J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

4.  MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.

Authors:  Chi Wai So; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

Review 5.  New insights for FOXO and cell-fate decision in HIV infection and HIV associated neurocognitive disorder.

Authors:  Min Cui; Yunlong Huang; Yong Zhao; Jialin Zheng
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 6.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

7.  Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A.

Authors:  Angharad M Shore; Paul C White; Rosaline C-Y Hui; Abdelkader Essafi; Eric W-F Lam; Martin Rowe; Paul Brennan
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

Review 8.  New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.

Authors:  Giada Zurlo; Jianping Guo; Mamoru Takada; Wenyi Wei; Qing Zhang
Journal:  Biochim Biophys Acta       Date:  2016-09-20

Review 9.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

10.  FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol.

Authors:  Rakesh K Srivastava; Terry G Unterman; Sharmila Shankar
Journal:  Mol Cell Biochem       Date:  2009-12-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.